{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T23:52:18Z","timestamp":1794009138807,"version":"4.8.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T00:00:00Z","timestamp":1671667200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T00:00:00Z","timestamp":1671667200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR001881"],"award-info":[{"award-number":["UL1TR001881"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008216","name":"UC | UCLA | UCLA Jonsson Comprehensive Cancer Center | Jonsson Cancer Center Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008216","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat. Biomed. Eng"],"DOI":"10.1038\/s41551-022-00977-0","type":"journal-article","created":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T12:04:23Z","timestamp":1671710663000},"page":"56-71","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Systemic enhancement of antitumour immunity by peritumourally implanted immunomodulatory macroporous scaffolds"],"prefix":"10.1038","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2049-5317","authenticated-orcid":false,"given":"Fatemeh S.","family":"Majedi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Mahdi","family":"Hasani-Sadrabadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy J.","family":"Thauland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sundeep G.","family":"Keswani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4760-8828","authenticated-orcid":false,"given":"Song","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4151-5628","authenticated-orcid":false,"given":"Louis-S.","family":"Bouchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4490-5595","authenticated-orcid":false,"given":"Manish J.","family":"Butte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,22]]},"reference":[{"key":"977_CR1","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ccell.2015.08.004","volume":"28","author":"R Dahan","year":"2015","unstructured":"Dahan, R. et al. Fc\u03b3Rs modulate the anti-tumor activity of antibodies targeting the PD-1\/PD-L1 axis. Cancer Cell 28, 285\u2013295 (2015).","journal-title":"Cancer Cell"},{"key":"977_CR2","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1084\/jem.20130579","volume":"210","author":"TR Simpson","year":"2013","unstructured":"Simpson, T. R. et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J. Exp. Med. 210, 1695\u20131710 (2013).","journal-title":"J. Exp. Med."},{"key":"977_CR3","doi-asserted-by":"publisher","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","volume":"28","author":"JBAG Haanen","year":"2017","unstructured":"Haanen, J. B. A. G. et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 28, iv119\u2013iv142 (2017).","journal-title":"Ann. Oncol."},{"key":"977_CR4","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1093\/annonc\/mdv623","volume":"27","author":"S Champiat","year":"2016","unstructured":"Champiat, S. et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann. Oncol. 27, 559\u2013574 (2016).","journal-title":"Ann. Oncol."},{"key":"977_CR5","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1093\/annonc\/mdw141","volume":"27","author":"J Naidoo","year":"2016","unstructured":"Naidoo, J. et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann. Oncol. 27, 1362 (2016).","journal-title":"Ann. Oncol."},{"key":"977_CR6","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1038\/s41590-020-0769-3","volume":"21","author":"S Kumagai","year":"2020","unstructured":"Kumagai, S. et al. The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies. Nat. Immunol. 21, 1346\u20131358 (2020).","journal-title":"Nat. Immunol."},{"key":"977_CR7","doi-asserted-by":"crossref","unstructured":"Sasada, T., Kimura, M., Yoshida, Y., Kanai, M. & Takabayashi, A. CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. Cancer 98, 1089\u20131099 (2003).","DOI":"10.1002\/cncr.11618"},{"key":"977_CR8","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/nm1093","volume":"10","author":"TJ Curiel","year":"2004","unstructured":"Curiel, T. J. et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10, 942\u2013949 (2004).","journal-title":"Nat. Med."},{"key":"977_CR9","doi-asserted-by":"crossref","unstructured":"Sato, E. et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+\/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc. Natl Acad. Sci. USA 102, 18538\u201318543 (2005).","DOI":"10.1073\/pnas.0509182102"},{"key":"977_CR10","doi-asserted-by":"publisher","first-page":"15179","DOI":"10.1038\/srep15179","volume":"5","author":"B Shang","year":"2015","unstructured":"Shang, B., Liu, Y., Jiang, S. J. & Liu, Y. Prognostic value of tumor-infiltrating Foxp3+ regulatory T cells in cancers: a systematic review and meta-analysis. Sci. Rep. 5, 15179 (2015).","journal-title":"Sci. Rep."},{"key":"977_CR11","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1038\/s41467-021-21297-y","volume":"12","author":"M Xydia","year":"2021","unstructured":"Xydia, M. et al. Common clonal origin of conventional T cells and induced regulatory T cells in breast cancer patients. Nat. Commun. 12, 1119 (2021).","journal-title":"Nat. Commun."},{"key":"977_CR12","doi-asserted-by":"crossref","unstructured":"Thomas, D. A. & Massagu\u00e9, J. TGF-\u03b2 directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 8, 369\u2013380 (2005).","DOI":"10.1016\/j.ccr.2005.10.012"},{"key":"977_CR13","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan, S. et al. TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554, 544\u2013548 (2018).","journal-title":"Nature"},{"key":"977_CR14","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.immuni.2019.03.024","volume":"50","author":"E Batlle","year":"2019","unstructured":"Batlle, E. & Massagu\u00e9, J. Transforming growth factor-\u03b2 signaling in immunity and cancer. Immunity 50, 924\u2013940 (2019).","journal-title":"Immunity"},{"key":"977_CR15","unstructured":"Stauber, A. J., Credille, K. M., Truex, L. L., Ehlhardt, W. J. & Young, J. K. Nonclinical safety evaluation of a transforming growth factor \u03b2 receptor I kinase inhibitor in Fischer 344 rats and beagle dogs. J. Clin. Toxicol. 4, 1\u201310 (2014)."},{"key":"977_CR16","first-page":"4479","volume":"9","author":"S Herbertz","year":"2015","unstructured":"Herbertz, S. et al. Clinical development of galunisertib (Ly2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway. Drug Des. Devel. Ther. 9, 4479\u20134499 (2015).","journal-title":"Drug Des. Devel. Ther."},{"key":"977_CR17","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1038\/nmat3355","volume":"11","author":"J Park","year":"2012","unstructured":"Park, J. et al. Combination delivery of TGF-\u03b2 inhibitor and IL-2 by nanoscale liposomal polymeric gels enhances tumour immunotherapy. Nat. Mater. 11, 895\u2013905 (2012).","journal-title":"Nat. Mater."},{"key":"977_CR18","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1038\/nrc2250","volume":"7","author":"MP Colombo","year":"2007","unstructured":"Colombo, M. P. & Piconese, S. Regulatory T-cell inhibition versus depletion: the right choice in cancer immunotherapy. Nat. Rev. Cancer 7, 880\u2013887 (2007).","journal-title":"Nat. Rev. Cancer"},{"key":"977_CR19","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1158\/0008-5472.CAN-18-1250","volume":"79","author":"X Zhou","year":"2019","unstructured":"Zhou, X. et al. Precise spatiotemporal interruption of regulatory T-cell-mediated CD8+ T-cell suppression leads to tumor immunity. Cancer Res. 79, 585\u2013597 (2019).","journal-title":"Cancer Res."},{"key":"977_CR20","first-page":"3128","volume":"59","author":"S Onizuka","year":"1999","unstructured":"Onizuka, S. et al. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor \u03b1) monoclonal antibody. Cancer Res. 59, 3128\u20133133 (1999).","journal-title":"Cancer Res."},{"key":"977_CR21","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1002\/eji.201847659","volume":"49","author":"A Tanaka","year":"2019","unstructured":"Tanaka, A. & Sakaguchi, S. Targeting Treg cells in cancer immunotherapy. Eur. J. Immunol. 49, 1140\u20131146 (2019).","journal-title":"Eur. J. Immunol."},{"key":"977_CR22","doi-asserted-by":"publisher","first-page":"352ra110","DOI":"10.1126\/scitranslmed.aaf6843","volume":"8","author":"K Sato","year":"2016","unstructured":"Sato, K. et al. Spatially selective depletion of tumor-associated regulatory T cells with near-infrared photoimmunotherapy. Sci. Transl. Med. 8, 352ra110 (2016).","journal-title":"Sci. Transl. Med."},{"key":"977_CR23","doi-asserted-by":"publisher","first-page":"e20200053","DOI":"10.1084\/jem.20200053","volume":"217","author":"KP Meng","year":"2020","unstructured":"Meng, K. P., Majedi, F. S., Thauland, T. J. & Butte, M. J. Mechanosensing through YAP controls T cell activation and metabolism. J. Exp. Med. 217, e20200053 (2020).","journal-title":"J. Exp. Med."},{"key":"977_CR24","doi-asserted-by":"publisher","first-page":"120058","DOI":"10.1016\/j.biomaterials.2020.120058","volume":"252","author":"FS Majedi","year":"2020","unstructured":"Majedi, F. S. et al. T-cell activation is modulated by the 3D mechanical microenvironment. Biomaterials 252, 120058 (2020).","journal-title":"Biomaterials"},{"key":"977_CR25","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.semcancer.2005.11.006","volume":"16","author":"K Khazaie","year":"2006","unstructured":"Khazaie, K. & von Boehmer, H. The impact of CD4+CD25+ Treg on tumor specific CD8+ T cell cytotoxicity and cancer. Semin. Cancer Biol. 16, 124\u2013136 (2006).","journal-title":"Semin. Cancer Biol."},{"key":"977_CR26","doi-asserted-by":"publisher","first-page":"eaak9702","DOI":"10.1126\/scisignal.aak9702","volume":"10","author":"S Budhu","year":"2017","unstructured":"Budhu, S. et al. Blockade of surface-bound TGF-\u03b2 on regulatory T cells abrogates suppression of effector T cell function in the tumor microenvironment. Sci. Signal. 10, eaak9702 (2017).","journal-title":"Sci. Signal."},{"key":"977_CR27","doi-asserted-by":"publisher","unstructured":"Pulaski, B. A. & Ostrand-Rosenberg, S. Mouse 4T1 breast tumor model. Curr. Protoc. Immunol. https:\/\/doi.org\/10.1002\/0471142735.im2002s39 (2001).","DOI":"10.1002\/0471142735.im2002s39"},{"key":"977_CR28","doi-asserted-by":"publisher","first-page":"101435","DOI":"10.1016\/j.smim.2020.101435","volume":"49","author":"J Han","year":"2020","unstructured":"Han, J., Khatwani, N., Searles, T. G., Turk, M. J. & Angeles, C. V. Memory CD8+ T cell responses to cancer. Semin. Immunol. 49, 101435 (2020).","journal-title":"Semin. Immunol."},{"key":"977_CR29","doi-asserted-by":"publisher","first-page":"5262","DOI":"10.1158\/1078-0432.CCR-07-1157","volume":"13","author":"SH Wrzesinski","year":"2007","unstructured":"Wrzesinski, S. H., Wan, Y. Y. & Flavell, R. A. Transforming growth factor-\u03b2 and the immune response: implications for anticancer therapy. Clin. Cancer Res. 13, 5262\u20135270 (2007).","journal-title":"Clin. Cancer Res."},{"key":"977_CR30","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1158\/1535-7163.MCT-06-0709","volume":"6","author":"L Novak","year":"2007","unstructured":"Novak, L., Igoucheva, O., Cho, S. & Alexeev, V. Characterization of the CCL21-mediated melanoma-specific immune responses and in situ melanoma eradication. Mol. Cancer Ther. 6, 1755\u20131764 (2007).","journal-title":"Mol. Cancer Ther."},{"key":"977_CR31","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41573-018-0006-z","volume":"18","author":"RS Riley","year":"2019","unstructured":"Riley, R. S., June, C. H., Langer, R. & Mitchell, M. J. Delivery technologies for cancer immunotherapy. Nat. Rev. Drug Discov. 18, 175\u2013196 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"977_CR32","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1172\/JCI87624","volume":"127","author":"TT Smith","year":"2017","unstructured":"Smith, T. T. et al. Biopolymers codelivering engineered T cells and STING agonists can eliminate heterogeneous tumors. J. Clin. Invest. 127, 2176\u20132191 (2017).","journal-title":"J. Clin. Invest."},{"key":"977_CR33","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nbt.3104","volume":"33","author":"SB Stephan","year":"2015","unstructured":"Stephan, S. B. et al. Biopolymer implants enhance the efficacy of adoptive T-cell therapy. Nat. Biotechnol. 33, 97\u2013101 (2015).","journal-title":"Nat. Biotechnol."},{"key":"977_CR34","doi-asserted-by":"crossref","unstructured":"Tahmasebi, S., Elahi, R. & Esmaeilzadeh, A. Solid tumors challenges and new insights of CAR T cell engineering. Stem Cell Rev. Rep. 15, 619\u2013636 (2019).","DOI":"10.1007\/s12015-019-09901-7"},{"key":"977_CR35","doi-asserted-by":"publisher","unstructured":"Tang, L. et al. Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery. Nat. Biotechnol. https:\/\/doi.org\/10.1038\/nbt.4181 (2018).","DOI":"10.1038\/nbt.4181"},{"key":"977_CR36","doi-asserted-by":"publisher","unstructured":"Mansurov, A. et al. Collagen-binding IL-12 enhances tumour inflammation and drives the complete remission of established immunologically cold mouse tumours. Nat. Biomed. Eng. https:\/\/doi.org\/10.1038\/s41551-020-0549-2 (2020).","DOI":"10.1038\/s41551-020-0549-2"},{"key":"977_CR37","doi-asserted-by":"publisher","first-page":"1703178","DOI":"10.1002\/adma.201703178","volume":"30","author":"FS Majedi","year":"2018","unstructured":"Majedi, F. S. et al. Cytokine secreting microparticles engineer the fate and the effector functions of T-cells. Adv. Mater. 30, 1703178 (2018).","journal-title":"Adv. Mater."},{"key":"977_CR38","first-page":"4251","volume":"60","author":"M Stohrer","year":"2000","unstructured":"Stohrer, M., Boucher, Y., Stangassinger, M. & Jain, R. K. Oncotic pressure in solid tumors is elevated. Cancer Res. 60, 4251\u20134255 (2000).","journal-title":"Cancer Res."},{"key":"977_CR39","first-page":"814","volume":"50","author":"RK Jain","year":"1990","unstructured":"Jain, R. K. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res. 50, 814\u2013819 (1990).","journal-title":"Cancer Res."},{"key":"977_CR40","doi-asserted-by":"publisher","first-page":"261ra151","DOI":"10.1126\/scitranslmed.3010162","volume":"6","author":"PS Adusumilli","year":"2014","unstructured":"Adusumilli, P. S. et al. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Sci. Transl. Med. 6, 261ra151 (2014).","journal-title":"Sci. Transl. Med."},{"key":"977_CR41","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/cgt.2016.14","volume":"23","author":"SC Katz","year":"2016","unstructured":"Katz, S. C. et al. Regional CAR-T cell infusions for peritoneal carcinomatosis are superior to systemic delivery. Cancer Gene Ther. 23, 142\u2013148 (2016).","journal-title":"Cancer Gene Ther."},{"key":"977_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40425-018-0340-z","volume":"6","author":"A Nellan","year":"2018","unstructured":"Nellan, A. et al. Durable regression of medulloblastoma after regional and intravenous delivery of anti-HER2 chimeric antigen receptor T cells. J. Immunother. Cancer 6, 1\u201314 (2018).","journal-title":"J. Immunother. Cancer"},{"key":"977_CR43","doi-asserted-by":"publisher","unstructured":"Waldron, K. et al. Formation of monodisperse mesoporous silica microparticles via spray-drying. J. Colloid Interface Sci. https:\/\/doi.org\/10.1016\/j.jcis.2013.12.027 (2014).","DOI":"10.1016\/j.jcis.2013.12.027"},{"key":"977_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.partic.2015.04.001","volume":"22","author":"W Liu","year":"2015","unstructured":"Liu, W., Chen, X. D. & Selomulya, C. On the spray drying of uniform functional microparticles. Particuology 22, 1\u201312 (2015).","journal-title":"Particuology"},{"key":"977_CR45","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S0278-6915(99)00159-3","volume":"38","author":"RJ Dearman","year":"2000","unstructured":"Dearman, R. J., Caddick, H., Basketter, D. A. & Kimber, I. Divergent antibody isotype responses induced in mice by systemic exposure to proteins: a comparison of ovalbumin with bovine serum albumin. Food Chem. Toxicol. 38, 351\u2013360 (2000).","journal-title":"Food Chem. Toxicol."},{"key":"977_CR46","doi-asserted-by":"publisher","first-page":"3431","DOI":"10.2217\/nnm.15.162","volume":"10","author":"MM Hasani-Sadrabadi","year":"2015","unstructured":"Hasani-Sadrabadi, M. M. et al. On-chip synthesis of fine-tuned bone-seeking hybrid nanoparticles. Nanomedicine 10, 3431\u20133449 (2015).","journal-title":"Nanomedicine"},{"key":"977_CR47","unstructured":"Sterilization of Health Care Products\u2014Radiation\u2014Part 2: Establishing the Sterilization Dose\u2014Technical Corrigendum 1 (ISO, 2009)."},{"key":"977_CR48","doi-asserted-by":"crossref","unstructured":"Bellone, M. et al. Relevance of the tumor antigen in the validation of three vaccination strategies for melanoma. J. Immunol. 165, 2651\u20132656 (2000).","DOI":"10.4049\/jimmunol.165.5.2651"}],"container-title":["Nature Biomedical Engineering"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41551-022-00977-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41551-022-00977-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41551-022-00977-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T12:05:53Z","timestamp":1674475553000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41551-022-00977-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,22]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["977"],"URL":"https:\/\/doi.org\/10.1038\/s41551-022-00977-0","relation":{},"ISSN":["2157-846X"],"issn-type":[{"value":"2157-846X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,22]]},"assertion":[{"value":"22 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Regents of the University of California filed patent applications (PCT\/US2020\/051363 and WO2021055658A1) related to this study, with F.S.M, M.M.H.-S. and M.J.B. as inventors. F.S.M, M.M.H.-S. and M.J.B. are founders and equity holders in Symphony Biosciences. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}